ArticleBMC infectious diseases2025
Tracking the pandemic through molecular and sequencing tools: a story of SARS- CoV-2 over five years, lessons learned, and further directions.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic posed unprecedented challenges to public health surveillance frameworks. In response, the Provincial Public Health Laboratory (PPHL), Sindh, contributed to early detection, large-scale diagnostic testing, and genomic surveillance from February 2020 to June 2025. This study reviews five years of PPHL's role in COVID-19 diagnosis, variant tracking, and public health response in Sindh. Diagnostic data included positive cases, while genomic epidemiology was assessed using commercial RT-PCR kits and in-house S-gene dropout assays as proxy tools for variant detection, supplemented by whole genome sequencing (WGS). A total of 194,415 specimens were tested, with five major peaks observed: wild-type (33.3%), Alpha (26.9%), Delta (22.0%), and Omicron (23.1%). WGS was performed on 124 selected samples, which identified Delta (AY.127, B.1.617.2), Omicron (BA.1, BA.5.2, XBB.1.9.1), and, more recently, JN.1, BA.2.86.1, and XEC lineages in May 2025. Reports of NB.1.8.1 from neighboring countries were noted, but this lineage was not detected in Karachi samples. While study limitations like low portion of sequenced samples and potential bias toward low Ct specimens exist, these findings still highlight the value of sustained laboratory-based surveillance in documenting SARS-CoV-2 evolution and supporting public health decision-making in Sindh.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.